Drug Profile
Nelitolimod - TriSalus Life Sciences
Alternative Names: ISS-ODN SD-101; SD-101; SD101-DynavaxLatest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Developer Bristol-Myers Squibb; Dynavax Technologies; Merck & Co; National Cancer Institute (USA); Stanford University School of Medicine; TriSalus Life Sciences; University of California, Davis
- Class Antineoplastics; Antivirals; Immunotherapies; Oligodeoxyribonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II B-cell lymphoma; Cholangiocarcinoma; Follicular lymphoma; Head and neck cancer; Liver cancer; Lymphoma; Malignant melanoma
- Phase I Pancreatic cancer; Uveal melanoma
- Preclinical Colorectal cancer
- No development reported Haematological malignancies; Hepatitis C; Solid tumours
Most Recent Events
- 01 Apr 2024 Pharmacokinetics, immunogenicity, efficacy and adverse events data from the phase-I PERIO-01 trial in Uveal melanoma released by TriSalus Life Sciences
- 01 Apr 2024 TriSalus Life Sciences completes enrolment in the phase-I PERIO-01 trial for Uveal melanoma (First-line therapy, Metastatic disease) in USA prior to April 2024
- 01 Apr 2024 TriSalus Life Sciences completes enrolment in the phase-I/II PERIO-02 trial for Liver cancer and Cholangiocarcinoma in USA prior to April 2024 (NCT05220722)